Publication:
Incidence of Lymphoproliferative Disorders After Renal Transplantation is Down, but the Poor Prognosis Remains. Multicenter 32-Year Cohort Study.

Simple item page
dc.contributor.authorFranco, Antonio
dc.contributor.authorHernandez, Domingo
dc.contributor.authorMas-Serrano, Patricio
dc.contributor.authorZarraga, Sofia
dc.contributor.authorSanchez, Ana
dc.contributor.authorCrespo, Marta
dc.contributor.authorMazuecos, Auxiliadora
dc.contributor.authorDiaz-Corte, Carmen
dc.contributor.authorRodriguez-Benot, Alberto
dc.contributor.authorJimenez, Carlos
dc.contributor.authorGonzalez, Yussel
dc.date.accessioned2023-05-03T15:19:05Z
dc.date.available2023-05-03T15:19:05Z
dc.date.issued2022-12-17
dc.description.abstractPost-transplant lymphoproliferative disorders represent rare but serious complications of kidney transplantation. We assessed incidence, risk factors, and outcomes in 21,546 patients receiving grafts between 1990 and 2009. Data were compared by decade of transplant (1990-1999 vs 2000-2009). Patients were followed for at least 12 years over a 32-year study period. In total, 331 patients (1.5%) developed PTLD: 189 of 9740 transplanted in the first decade, and 142 of 11,806 in the second. Incidence decreased significantly (19.40 vs12.02 cases/1000 patients; P Post-transplant lymphoproliferative disorders have a low and decreasing incidence, but the poor prognosis has not changed.
dc.description.versionSi
dc.identifier.citationFranco A, Hernández D, Más-Serrano P, Zarraga S, Sanchez A, Crespo M, et al. Incidence of Lymphoproliferative Disorders After Renal Transplantation is Down, but the Poor Prognosis Remains. Multicenter 32-Year Cohort Study. Transplant Proc. 2022 Nov;54(9):2462-2466
dc.identifier.doi10.1016/j.transproceed.2022.10.017
dc.identifier.essn1873-2623
dc.identifier.pmid36379722
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.transproceed.2022.10.017
dc.identifier.urihttp://hdl.handle.net/10668/22536
dc.issue.number9
dc.journal.titleTransplantation proceedings
dc.journal.titleabbreviationTransplant Proc
dc.language.isoen
dc.organizationHospital Universitario Puerta del Mar
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Regional de Málaga
dc.page.number2462-2466
dc.provenanceRealizada la curación de contenido 10/04/2025
dc.publisherElsevier
dc.pubmedtypeMulticenter Study
dc.pubmedtypeJournal Article
dc.relation.publisherversionhttps://linkinghub.elsevier.com/retrieve/pii/S0041-1345(22)00664-9
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectIncidence
dc.subjectHerpesvirus 4, Human
dc.subjectKidney Transplantation
dc.subjectEpstein-Barr Virus Infections
dc.subject.decsIncidencia
dc.subject.decsTrastornos Linfoproliferativos
dc.subject.decsTrasplante de Riñón
dc.subject.decsFactores de Riesgo
dc.subject.meshHumans
dc.subject.meshCohort Studies
dc.subject.meshPostoperative Complications
dc.subject.meshLymphoproliferative Disorders
dc.subject.meshRisk Factors
dc.subject.meshPrognosis
dc.subject.meshRetrospective Studies
dc.titleIncidence of Lymphoproliferative Disorders After Renal Transplantation is Down, but the Poor Prognosis Remains. Multicenter 32-Year Cohort Study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number54
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Franco_IncidenceOf.pdf
Size:
302.03 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Regional Universitario de Málaga
SAS - Hospital Universitario Puerta del Mar
SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía